Want to see AU:AGN full AI Analyst Report?
AGN Stock Chart & Stats
AU$0.18
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.18
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.77
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$17.98M
Enterprise ValueAU$9.09M
Total Cash (Recent Filing)AU$5.04M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$4.40M
Bulls Say, Bears Say
Bulls Say
Focused Drug-development NicheA clear strategic focus on neuroprotective therapeutics concentrates R&D resources and expertise on a defined clinical need. That specialization supports durable competitive positioning for partnership/licensing opportunities and clearer milestone-driven value creation over the next 2–6 months.
Sustained Revenue GrowthYear‑over‑year revenue scaling indicates program progress or commercialization of services and reduces binary dependency on a single milestone. Consistent top-line growth strengthens negotiating leverage with partners and underpins longer-term funding options if the trend persists.
Debt-free Balance SheetAbsence of debt lowers fixed financial obligations and bankruptcy risk, giving management flexibility to prioritize clinical development timelines or pursue partnerships without servicing debt. This structural simplicity supports survivability through typical biotech development cycles.
Bears Say
Deep, Persistent LossesVery large negative margins and persistent operating losses mean the business is not yet self-sustaining. Over the medium term this necessitates repeated external financing, increasing execution risk and potential dilution if clinical progress does not accelerate into value-accretive partnerships or milestones.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows create a structural funding requirement. Persistent burn increases dependency on capital markets or partner financing, compressing strategic optionality and raising the risk that development timelines are delayed if financing conditions worsen.
Sharp Equity Decline/dilution RiskA material drop in equity reflects prior losses and/or financing dilution, reducing the internal capital buffer available for R&D. This increases the probability of further equity raises, which can dilute shareholders and constrain long-term incentives unless offset by high-impact clinical progress or partner funding.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.09 and its highest was AU$0.77 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$17.98M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 227 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AGN Sentiment 93%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-183.51%
Trailing 12-Months
Asset Growth
-66.25%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―